|Company name||Moderna, Inc.|
NEW YORK, May 26, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Moderna, Inc. (NASDAQ: MRNA) on behalf of Moderna stockholders. Our investigation concerns whether Moderna has violated the federal securities laws and/or engaged in other unlawful business practices.
On May 18, 2020, Moderna announced Phase 1 trial results for a candidate vaccine for COVID-19 under development by the Company, indicating that the candidate appeared to generate an immune response similar to the response seen in individuals who have been infected by the virus and recovered. Specifically, Moderna reported that eight patients who received two doses of the vaccine at the lowest and middle doses tested – 25 and 100 micrograms – developed neutralizing antibodies to the virus at levels similar to people who had recovered from infection.
In the days following Moderna’s announcement, the Company’s announcement was the subject of skeptical commentary from multiple sources. For example, on May 19, 2020, STAT published an article entitled “Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine,” which noted, in part, that “[w]hile Moderna blitzed the media, it revealed very little information – and most of what it did disclose were words, not data.”
Over the three trading sessions following Moderna’s May 18, 2020 announcement, the Company’s stock price fell $12.95 per share, or 16.19%, to close at $67.05 per share on May 21, 2020.
If you purchased or otherwise acquired Moderna shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Marion Passmore or Melissa Fortunato by email at email@example.com, telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.